(Q24654724)
Statements
Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates (English)
0 references
July 2009
0 references
53
0 references
7
0 references
2879-86
0 references
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference